Grifols announced that the U.S. Food and Drug Administration has approved a new higher potency formulation of HyperRAB (rabies immune globulin [human]) for rabies post-exposure prophylaxis. The new formulation has twice the potency (300 IU/mL) of currently available rabies immune globulin options. This allows for fewer injections, along with a significantly lower volume of the … [Read more...]